Details:
The claims of the new patent protect combined therapeutic preparations comprising MP321 (eftilagimod alpha), which is a soluble LAG-3 fusion protein (LAG-3Ig), and an antiPD-1 or anti-PD-L1 antibody to manufacture of medicament for treatment of cancer and infectious disease.
Lead Product(s): Eftilagimod Alpha,Undisclosed
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021